Investigation of reduced vancomycin susceptibility in methicillin-resistant staphylococci;Metisiline dirençli stafilokoklarda azalmiş vankomisin duyarlilig̀min araştinlmasi

Mikrobiyoloji Bulteni

Volumn 45, Issue 2, 2011, Pages 248-257

  Kuşcu, Ferit ^a,b,d   Öztürk, Dog̀an Bariş ^a,b   Gürbüz, Yunus ^a,b   Tütüncü, Emin Ediz ^a,b   Şencan, Irtan ^a,b   Serdar, G U L ^c  

^a Enfeksiyon Hastaliklari ve Klinik Mikrobiyoloji Klini i   (Turkey)

^b DISKAPI YILDIRIM BEYAZIT TRAINING AND RESEARCH HOSPITAL   (Turkey)

^c Sorgun Devlet Hastanesi   (Turkey)

^d Osmanli Mahallesi Selin Sokak Yediel Sitesi   (Turkey)

Author keywords

Cogulase negative staphylococci; HVISA; Methicillin; Resistance; Staphylococcus aureus; Vancomycin; VISA

Indexed keywords

ANTIINFECTIVE AGENT; VANCOMYCIN;

ARTICLE; CLASSIFICATION; DRUG EFFECT; HUMAN; INTENSIVE CARE UNIT; ISOLATION AND PURIFICATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; PREVALENCE; STAPHYLOCOCCUS INFECTION; TURKEY (REPUBLIC);

ANTI-BACTERIAL AGENTS; HUMANS; INTENSIVE CARE UNITS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; PREVALENCE; STAPHYLOCOCCAL INFECTIONS; TURKEY; VANCOMYCIN;

EID: 79958752305     PISSN: 03749096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemoter 1997; 40(1): 135-6. (Pubitemid 27341646)
2. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis 2001; 1(3): 147-55. (Pubitemid 33586048)
3. Appelbaum PC. MRSA- the tip of the iceberg. Clin Microbiol Infect 2006; 12(Suppl 2): S3-10.
4. Moreira B, Boyle-Vavra S, de Jonge BL, Daum RS. Increased production of penicillin-binding protein 2, increased detection of other penicillin-binding proteins, and decreased coagulase activity associated with glycopeptide resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1997; 41(8): 1788-93. (Pubitemid 27339888)
5. Finan JE, Archer GL, Pucci MJ, Climo MW. Role of penicillin-binding protein 4 in expression of vancomycin resistance among clinical isolates of oxacillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2001; 45(11) : 3070-5. (Pubitemid 32988830)
6. Shorr AF. Epidemiology of staphylococcal resistance. Clin Infect Dis 2007; 45(Suppl 3): S171-6. (Pubitemid 47378903)
7. Sancak B. Staphylococcus aureut'ta metisilin ve vankomisin direnci. Hacettepe Tip Dergisi 2007; 38:127-34.
8. Rahman M. Alternatives to vancomycin in treating methicillin-resistant Staphylococcus aureus infections. J Antimicrob Chemother 1998; 41(3): 325-8. (Pubitemid 28151980)
9. th ed. Churchill Livingstone, Philadelphia.
10. Guerin F, Buu-Hoi A, Mainardi JL, et al. Outbreak of methicillin- resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in a Parisian hospital. J Clin Microbiol 2000; 38(8): 2985-8. (Pubitemid 30640585)
11. Fridkin SK. Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know. Clin Infect Dis 2001; 32(1): 108-15. (Pubitemid 32150955)
12. Tenover FC, Biddle JW, Lancaster MV. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis 2001; 7(2): 327-32. (Pubitemid 32374355)
13. Clinical and Laboratory Standards Institute. Antimikrobik Duyarlihk Testleri için Uygulama Standartlari. Onsekizinci Bilgi Eki, M100-S18, 2008. Gür D (Çeviri ed), Türk Mikrobiyoloji Cemiyeti Yayim, Istanbul.
14. Hiramatsu K, Aritaka N, Hanaki H, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogenously resistant to vancomycin. Lancet 1997; 350(9092): 1670-3. (Pubitemid 28036828)
15. Walsh TR, Bolmström A, Qwarnström A, et al. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol 2001; 39(7): 2439-44. (Pubitemid 32606216)
16. Wootton M, Howe RA, Hillman R, Walsh TR, Bennett PM, MacGowan AP. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother 2001; 47(4): 399-403. (Pubitemid 32303403)
17. Cul L, Ma X, Sato K, et al. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J Clin Microbiol 2003; 41(1): 5-14. (Pubitemid 36098547)
18. Liu C, Chambers HF. Staphylococcus aureus with heterogeneus resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob Agents Chemother 2003; 47(10): 3040-5. (Pubitemid 37229554)
19. Song JH, Hiramatsu K, Suh JY, et al. Emergence in Asian countries of Staphylococcus aureus with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 2004; 48(12): 4926-8. (Pubitemid 39577710)
20. Bobin-Dubreux S, Reverdy ME, Nervi C, et al. Clinical isolate of vancomycin-heterointermediate Staphylococcus aureus susceptible to methicillin and in vitro selection of a vancomycin-resistant derivative. Antimicrob Agents Chemother 2001; 45(1): 349-52. (Pubitemid 32039145)
21. Robert J, Bismuth R, Jarlier V. Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: a 20 year study in a large French teaching hospital, 1983-2002. J Antimicrob Chemother 2006; 57(3): 506-10. (Pubitemid 43240204)
22. Schmitz FJ, Krey A, Geisel R, Verhoef J, Heinz HP, Fluit AC. Susceptibility of 302 methicillin-resistant Staphylococcus aureus isolates from 20 European university hospitals to vancomycin and alternative antistaphylococcal compounds. Eur J Clin Microbiol Infect Dis 1999; 18(7): 528-30. (Pubitemid 29531200)
23. Marchese A, Balistreri G, Tonoli E, Debbia EA, Schito GC. Heterogeneous vancomycin resistance in methicillin-resistant Staphylococcus aureus strains isolated in a large Italian hospital. J Clin Microbiol 2000; 38(2): 866-9. (Pubitemid 30082697)
24. Trakulsomboon S, Danchaivijitr S, Rongrungruang Y, et al. First report of methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Thailand. J Clin Microbiol 2001; 39(2): 591-5. (Pubitemid 32150823)
25. Sancak B, Ercis S, Menemenlioglu D, Colakoglu S, Hasçelik G. Methicillin-resistant Staphylococcus aureus heterogeneously resistant to vancomycin in a Turkish university hospital. J Antimicrob Chemother 2005; 56(3): 519-23. (Pubitemid 41264130)
26. Nakipoglu Y, Derbentli S, Cagatay AA, Katranci H. Investigation of Staphylococcus strains with heterogeneous resistance to glycopeptides in a Turkish university hospital. BMC Infect Dis 2005; 5(1): 31.
27. Ariza J, Pujol M, Cabo J, et al. Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. Lancet 1999; 353(9164): 1587-8. (Pubitemid 29219213)
28. Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 2004; 38(3): 448-51. (Pubitemid 38200128)
29. Howden BP, Ward PB, Charles PG, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004; 38(4): 521-8. (Pubitemid 38250962)